Top

European Radiology

Published in:

01-11-2019 | Hepatobiliary-Pancreas

Targeted and non-targeted liver biopsies carry the same risk of complication

Authors: Anna Maheux, Yvonne Purcell, Sana Harguem, Valérie Vilgrain, Maxime Ronot

Published in: European Radiology | Issue 11/2019

Abstract

Objectives

To reappraise the rate of and risk factors for complications of targeted and non-targeted US-guided liver biopsy in a large series.

Methods

We analyzed 2405 liver biopsies performed in 2137 patients (58% males, mean age 54 ± 15 years old) between January 2010 and December 2015. Biopsies were performed for focal liver lesions characterization (targeted) or chronic liver disease assessment (non-targeted). Clinical, laboratory, and technical data were recorded. For targeted biopsies, we also recorded the largest diameter, location, enhancement pattern, and pathology. Advert events were divided into marked symptoms and complications. Those requiring specific treatment (embolization or surgery) were considered as severe.

Results

A total of 1283 (53%) targeted and 1122 (47%) non-targeted biopsies were performed. Marked symptoms occurred after 134 biopsies (5.6%) (95 (7.4%) targeted and 39 (3.5%) non-targeted, p < 0.001), the most common being pain (109/134). Complications occurred after 38 biopsies (1.6%) (24 (1.9%) targeted and 14 (1.2%) non-targeted, p = 0.253) and were severe in 13 patients. In univariate analysis, prothrombin time (p = 0.006), serum creatinine level (p < 0.001), largest lesion diameter (p < 0.001), and tumor pathology (p = 0.040) were associated with the occurrence of complications but not platelet count or lesion enhancement pattern. In multivariate analysis, only the largest lesion diameter was retained (OR 1.014 [1.002–1.026], p = 0.018).

Conclusion

The rate of advert events after US-guided liver biopsy was low, with no difference between targeted and non-targeted biopsies. When focusing on targeted biopsies, the largest lesion diameter but not enhancement pattern appeared as the main risk factor.

Key Points

• Targeted and non-targeted liver biopsies are associated with the same observed risk of complication.

• Arterial phase hyperenhanced tumors on contrast-enhanced CT or MRI are not associated with a higher risk of complication when compared with non-hyperenhanced ones.

• A high serum creatinine level is associated with a higher risk of complication and should motivate strict post-biopsy surveillance.

Available only for authorised users

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD (2009) Liver biopsy. Hepatology. 49:1017–1044CrossRef

Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344:495–500CrossRef

European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236CrossRef

Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67:358–380

European Association for the Study of the Liver (EASL) (2016) EASL Clinical Practice on the management of benign tumours J Hepatol 65:386–398

Grant A, Neuberger J (1999) Guidelines on the use of liver biopsy in clinical practice. Gut. 45(suppl 4):IV1–IV11PubMedPubMedCentral

Seeff LB, Everson GT, Morgan TR et al (2010) Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 8:877–883

McGill DB, Rakela J, Zinsmeister AR, Ott BJ (1990) A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 99:1396–1400CrossRef

Howlett DC, Drinkwater KJ, Lawrence D, Barter S, Nicholson T (2013) Findings of the UK national audit evaluating image-guided or image-assisted liver biopsy. Radiology. 266:226–235CrossRef

10.

Terjung B, Lemnitzer I, Dumoulin FL et al (2003) Bleeding complications after percutaneous liver biopsy. Digestion 67:138–145

11.

Froehlich F, Lamy O, Fried M, Gonvers JJ (1993) Practice and complications of liver biopsy. Dig Dis Sci 38:1480–1484CrossRef

12.

Mueller M, Kratzer W, Oeztuerk S et al (2012) Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol 12:1

13.

Farrell RJ, Smiddy PF, Pilkington RM et al (1999) Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 30:580–587

14.

Patel IJ, Davidson JC, Nikolic B et al (2012) Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 23:727–736CrossRef

15.

Alten TA, Negm AA, Voigtländer T et al (2014) Safety and performance of liver biopsies in liver transplant recipients. Clin Transplant 28:585–589

16.

Sharma P, McDonald GB, Banaji M (1982) The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 4:451–453CrossRef

17.

Sandrasegaran K, Thayalan N, Thavanesan R et al (2016) Risk factors for bleeding after liver biopsy. Abdom Radiol (NY). 41:643–649

18.

Filingeri V, Francioso S, Sforza D, Santopaolo F, Oddi FM, Tisone G (2016) A retrospective analysis of 1.011 percutaneous liver biopsies performed in patients with liver transplantation or liver disease: ultrasonography can reduce complications? Eur Rev Med Pharmacol Sci 20:3609–3617

19.

Vijayaraghavan GR, Vedantham S, Rangan V et al (2015) Effect of needle gauge and lobe laterality on parenchymal liver biopsy outcome: a retrospective analysis. Abdom Imaging 40:1223–1229

20.

Kose S, Ersan G, Tatar B, Adar P, Erturk Sengel EB (2015) Evaluation of percutaneous liver biopsy complications in patients with chronic viral hepatitis. Eurasian J Med 47:161–164

21.

Sherman KE, Goodman ZD, Sullivan ST, Faris-Young S, for the GILF Study Group (2007) Liver biopsy in cirrhotic patients. Am J Gastroenterol 102:789–793CrossRef

22.

Cadranel JF, Rufat P, Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).. Hepatology. 32:477–481

23.

Strobel D, Bernatik T, Blank W et al (2015) Incidence of bleeding in 8172 percutaneous ultrasound-guided intraabdominal diagnostic and therapeutic interventions – results of the prospective multicenter DEGUM interventional ultrasound study (PIUS study). Ultraschall Med 36:122–131

24.

McVay PA, Toy PT (1990) Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 94:747–753

25.

Chi H, Hansen BE, Tang WY et al (2017) Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. Eur J Gastroenterol Hepatol 29:36–41

26.

Yu SC, Metreweli C, Lau WY, Leung WT, Liew CT, Leung NW (1997) Safety of percutaneous biopsy of hepatocellular carcinoma with an 18 gauge automated needle. Clin Radiol 52:907–911CrossRef

27.

Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 36:437–441CrossRef

28.

Thampanitchawong P, Piratvisuth T (1999) Liver biopsy: complications and risk factors. World J Gastroenterol 5:301CrossRef

29.

Piccinino F, Sagnelli E, Pasquale G, Giusti G (1986) Complications following percutaneous liver biopsy: a multicentre retrospective study on 68 276 biopsies. J Hepatol 2:165–173

30.

Kitchin DR, Del Rio AM, Woods M, Ludeman L, Hinshaw JL (2018) Percutaneous liver biopsy and revised coagulation guidelines: a 9-year experience. Abdom Radiol 43:1494–1501CrossRef

31.

Acedillo RR, Shah M, Devereaux PJ et al (2013) The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Surg 258:901–913

32.

Jalal D, Chonchol M, Targher G (2010) Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 36:34–40CrossRef

33.

Pavord S, Myers B (2011) Bleeding and thrombotic complications of kidney disease. Blood Rev 25:271–278CrossRef

34.

Weeder PD, Porte RJ, Lisman T (2014) Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 28:107–113CrossRef

35.

Myers RP, Fong A, Shaheen AA (2008) Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies: population-based study of percutaneous liver biopsy. Liver Int 28:705–712CrossRef

36.

Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660CrossRef

37.

Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427CrossRef

38.

He MQ, He MQ, Wang JF et al (2016) Vascular endothelial growth factor and cluster of differentiation 34 for assessment of perioperative bleeding risk in gastric cancer patients. Chin Med J (Engl) 129:1950

39.

Atwell TD, Smith RL, Hesley GK et al (2010) Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol 194:784–789

Title: Targeted and non-targeted liver biopsies carry the same risk of complication
Authors: Anna Maheux
Yvonne Purcell
Sana Harguem
Valérie Vilgrain
Maxime Ronot
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 11/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-019-06227-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Targeted and non-targeted liver biopsies carry the same risk of complication

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 11/2019

Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation

Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?

Value of early repeated abdominal CT in selective non-operative management for blunt bowel and mesenteric injury

Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation

Non-contrast MR lymphography of the lymphatic system of the liver

Standardized volumetric plaque quantification and characterization from coronary CT angiography: a head-to-head comparison with invasive intravascular ultrasound